Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMD 521873 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Group 1 | EXPERIMENTAL | Dose escalation of EMD 521873 monotheraphy 3 doses per cycle |
| Group 2 | EXPERIMENTAL | Low dose CPA + Dose escalation of EMD 521873 three doses per cycle |
| Group 3 | EXPERIMENTAL | Dose escalation of EMD 521873 monotheraphy 1 dose per cycle |
| Name | Type | Description |
|---|---|---|
| EMD 521873 | BIOLOGICAL | After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively. |
Inclusion Criteria: * Histologically or cytologically confirmed NSCLC stage IIIb with malignant pleural effusion or stage IV * Pulmonary primary tumor or at least one NSCLC metastasis in the lung measuring at least 1 cm in diameter and eligible for local radiation with 20 Gy * Disease control (part...
Top 20 of 75 competitors
EMD 521873 is an investigational monoclonal antibody being developed by Merck KGaA for oncology. It has been studied in Phase 1 clinical trials in patients with advanced solid tumors, non-Hodgkin lymphoma, and non-small cell lung cancer. It is not an approved therapy and remains in clinical development.
EMD 521873 was studied in Phase 1 for non-small cell lung cancer, where it was evaluated in combination with radiotherapy. The trial enrolled 15 patients in the Netherlands. The drug is investigational and has not been approved for lung cancer or any other indication.
EMD 521873 was evaluated in a Phase 1 dose-finding study in patients with advanced solid tumors, including non-Hodgkin lymphoma. That trial enrolled 66 patients across Germany and Switzerland. The study is complete, and the drug remains investigational rather than approved for lymphoma treatment.
EMD 521873 is developed by Merck KGaA, which trades over the counter in the United States under the ticker MKGAF. The compound is an investigational monoclonal antibody in the company's oncology pipeline and has been tested in Phase 1 clinical studies.
EMD 521873 is in Phase 1 development. Both of its recorded clinical trials were Phase 1 studies, and both are now completed. No later-phase trials have been registered, and the drug has not been approved by the FDA or any other regulator.
EMD 521873 has been studied in two completed Phase 1 trials. NCT01032681 tested the antibody in advanced solid tumors including non-Hodgkin lymphoma in Germany and Switzerland, enrolling 66 patients. NCT00879866 tested EMD 521873 plus radiotherapy in non-small cell lung cancer in the Netherlands, enrolling 15 patients.